
Chembio Diagnostics CEMI
Annual report 2022
added 03-29-2023
Chembio Diagnostics DIO Ratio 2011-2026 | CEMI
Annual DIO Ratio Chembio Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 97.6 | 135 | 191 | 156 | 134 | 125 | 129 | 94.9 | 78.9 | 67.5 | 61.3 | 84 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 191 | 61.3 | 113 |
Quarterly DIO Ratio Chembio Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 40 | - | 74.2 | - | 188 | 343 | 350 | - | 153 | 201 | 231 | - | 132 | 125 | 159 | - | 31.7 | 116 | 127 | - | 99.3 | 183 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 350 | 31.7 | 160 |
DIO Ratio of other stocks in the Diagnostics research industry
| Issuer | DIO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
25.4 | - | -6.23 % | $ 30.6 M | ||
|
ICON Public Limited Company
ICLR
|
0.213 | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Aspira Women's Health
AWH
|
23.1 | - | -6.19 % | $ 10.5 M | ||
|
Charles River Laboratories International
CRL
|
35.3 | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Bioventus
BVS
|
177 | $ 8.62 | 0.23 % | $ 574 M | ||
|
DexCom
DXCM
|
115 | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
210 | - | - | $ 562 M | ||
|
Castle Biosciences
CSTL
|
48.7 | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
48.3 | $ 17.01 | 3.4 % | $ 906 M | ||
|
Accelerate Diagnostics
AXDX
|
198 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
60.9 | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Guardant Health
GH
|
82.1 | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
Global Cord Blood Corporation
CO
|
89.7 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
131 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
42.1 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
62.8 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
7.17 | $ 14.77 | 0.61 % | $ 447 M | ||
|
Danaher Corporation
DHR
|
87.6 | $ 187.32 | 0.57 % | $ 134 B | ||
|
Biocept
BIOC
|
21.9 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
137 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
116 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
137 | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
9.34 | $ 199.7 | -0.46 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
141 | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
97.1 | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
245 | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
165 | $ 9.0 | -0.99 % | $ 255 M | ||
|
Neogen Corporation
NEOG
|
147 | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
Pacific Biosciences of California
PACB
|
173 | $ 1.33 | 4.72 % | $ 399 M | ||
|
Co-Diagnostics
CODX
|
304 | - | - | $ 79.8 M | ||
|
DermTech
DMTK
|
33.5 | - | -11.32 % | $ 2.94 M | ||
|
Mettler-Toledo International
MTD
|
79 | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Personalis
PSNL
|
12.1 | $ 6.72 | 1.97 % | $ 398 M | ||
|
NeoGenomics
NEO
|
24.4 | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
156 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
25.8 | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Sotera Health Company
SHC
|
36.5 | $ 13.42 | 0.71 % | $ 3.81 B | ||
|
Invitae Corporation
NVTA
|
126 | - | - | $ 21.2 M | ||
|
OPKO Health
OPK
|
45.2 | $ 1.19 | 2.59 % | $ 826 M |